journal article·2024-12-27

Multifunctional Biomimetic Hollow Nanoparticles with Inhibiting Thioredoxin Reductase Activity for Cancer Therapy

Chuanye Tang, Danjie Song, Pinghua Ling, Wenwen Xu, Yalong Qiao, Fang Wang

ACS Applied Nano Materials· Volume 7· Issue 24
Publisher page

Abstract

Cell redox homeostasis plays an important role in mediating cellular reactions and regulating biological responses. Up to now, numerous methods based on disrupting cellular redox homeostasis have been developed for cancer therapy, but the treatment efficacy remains a challenges. Thioredoxin reductase (TrxR) is highly overexpressed in cancer cells, promoting malignant tumor survival. Inhibiting TrxR activity presents a promising approach to perturbing cellular redox homeostasis for cancer chemotherapy. Herein, we reported a novel strategy utilizing multifunctional biomimetic hollow nanoparticles (IrSe 2 ) that effectively inhibit TrxR activity, exhibit high reactive oxygen species (ROS) generation capacity, and catalyze a cascade of intracellular biochemical reactions for the treatment of breast cancer. In this system, IrSe 2 nanoparticles could inhibit TrxR activity and deplete glutathione (GSH), thereby disrupting the antioxidant defense system and further improving intracellular ROS levels. Furthermore, IrSe 2 nanoparticles are simultaneously featured with peroxidase- and oxidase-like activities, generating increased ROS. Both in vitro and in vivo experimental results reveal that the anticancer activity of IrSe 2 is mediated by its nanozyme activity and inhibition of both TrxR and GSH activity, leading to apoptosis. This work not only paves a new way for designing high-performance nanozymes and nanocatalysts for practical applications but also underscores the potential of combining TrxR and GSH inhibition to disrupt cellular redox homeostasis and enhance ROS release as a promising strategy for breast cancer therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Nanocluster Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Province Key Laboratory of Biomedical Materials and Chemical Measurement, College of Chemistry and Materials Science

Anhui Normal University

Institute of Clinical Pharmacy, Jining No. 1 People’s Hospital

Shandong First Medical University

Funding

University Natural Science Research Project of Anhui Province · National Natural Science Foundation of China · Natural Science Foundation of Shandong Province · Doctoral Fund of Jining NO.1 People?s Hospital

References (59)

Show source-provided references
1. 10.1021/acsnano.9b0942610.1021/acsnano.9b09426 ↗
2. 10.1002/anie.20221041510.1002/anie.202210415 ↗
3. 10.1002/anie.20230225510.1002/anie.202302255 ↗
4. 10.1021/acsnano.2c0602610.1021/acsnano.2c06026 ↗
5. 10.1002/anie.20220450210.1002/anie.202204502 ↗
6. 10.1039/D1CS00494H10.1039/D1CS00494H ↗
7. 10.1021/acsnano.1c0904810.1021/acsnano.1c09048 ↗
8. 10.1002/smll.20220726110.1002/smll.202207261 ↗
9. 10.1002/adma.20210012910.1002/adma.202100129 ↗
10. 10.1021/acsnano.9b0616810.1021/acsnano.9b06168 ↗
11. 10.1002/adfm.20210216010.1002/adfm.202102160 ↗
12. 10.1002/anie.20200743410.1002/anie.202007434 ↗
13. 10.1021/acsnano.1c0143510.1021/acsnano.1c01435 ↗
14. 10.1021/acsnano.2c0860410.1021/acsnano.2c08604 ↗
15. 10.1186/s12951-022-01654-910.1186/s12951-022-01654-9 ↗
16. 10.1021/acsami.1c0661310.1021/acsami.1c06613 ↗
17. 10.1016/j.nantod.2022.10157410.1016/j.nantod.2022.101574 ↗
18. 10.1016/j.cej.2022.13499310.1016/j.cej.2022.134993 ↗
19. 10.1016/j.bios.2021.11337710.1016/j.bios.2021.113377 ↗
20. 10.7150/thno.5780310.7150/thno.57803 ↗
21. 10.1073/pnas.070154910410.1073/pnas.0701549104 ↗
22. 10.1016/j.freeradbiomed.2022.01.01910.1016/j.freeradbiomed.2022.01.019 ↗
23. 10.1002/anie.20200004810.1002/anie.202000048 ↗
24. 10.1016/j.semcancer.2006.10.00910.1016/j.semcancer.2006.10.009 ↗
25. 10.1016/j.freeradbiomed.2013.07.03610.1016/j.freeradbiomed.2013.07.036 ↗
26. 10.1016/j.tips.2017.06.00110.1016/j.tips.2017.06.001 ↗
27. 10.1016/j.phrs.2021.10585410.1016/j.phrs.2021.105854 ↗
28. 10.1042/bj346000110.1042/bj3460001 ↗
29. 10.1021/acsami.7b0705610.1021/acsami.7b07056 ↗
30. 10.1016/j.biomaterials.2019.11950010.1016/j.biomaterials.2019.119500 ↗
31. 10.1021/jacs.2c0880210.1021/jacs.2c08802 ↗
32. 10.1002/advs.20230863210.1002/advs.202308632 ↗
33. 10.1039/D0CS00718H10.1039/D0CS00718H ↗
34. 10.1016/j.biomaterials.2021.12111010.1016/j.biomaterials.2021.121110 ↗
35. 10.3389/fmolb.2020.57642010.3389/fmolb.2020.576420 ↗
36. 10.1002/adhm.20210275910.1002/adhm.202102759 ↗
37. 10.1021/acsnano.1c0846410.1021/acsnano.1c08464 ↗
38. 10.1002/adhm.20230192410.1002/adhm.202301924 ↗
39. 10.1039/D0CS00659A10.1039/D0CS00659A ↗
40. 10.1016/j.ccr.2021.21421610.1016/j.ccr.2021.214216 ↗
41. 10.1016/j.nantod.2021.10126910.1016/j.nantod.2021.101269 ↗
42. 10.1021/acssuschemeng.3c0472910.1021/acssuschemeng.3c04729 ↗
43. 10.1016/j.actbio.2023.08.05510.1016/j.actbio.2023.08.055 ↗
44. 10.1002/anie.20230446510.1002/anie.202304465 ↗
45. 10.1021/acsnano.2c0731110.1021/acsnano.2c07311 ↗
46. 10.1002/adfm.20230205410.1002/adfm.202302054 ↗
47. 10.1021/acs.nanolett.3c0106810.1021/acs.nanolett.3c01068 ↗
48. 10.1021/acsami.3c0510010.1021/acsami.3c05100 ↗
49. 10.1016/j.nantod.2023.10211310.1016/j.nantod.2023.102113 ↗
50. 10.1021/acscatal.3c0288710.1021/acscatal.3c02887 ↗
51. 10.1021/acscatal.1c0216510.1021/acscatal.1c02165 ↗
52. 10.1021/ja505716v10.1021/ja505716v ↗
53. 10.1016/j.snb.2016.11.14510.1016/j.snb.2016.11.145 ↗
54. 10.1021/acsami.2c0395210.1021/acsami.2c03952 ↗
55. 10.1039/D0NR06601J10.1039/D0NR06601J ↗
56. 10.1039/C5NR05748E10.1039/C5NR05748E ↗
57. 10.1021/jacs.2c1277210.1021/jacs.2c12772 ↗
58. 10.1002/anie.20180771710.1002/anie.201807717 ↗
59. 10.1002/anie.20150340710.1002/anie.201503407 ↗